Grants and Contracts Details
Description
ABSTRACT
To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk
neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of
patients who are not assigned to treatment that includes early chemoimmunotherapy.
| Status | Active |
|---|---|
| Effective start/end date | 5/15/24 → 5/14/34 |
Funding
- Public Health Institute: $2.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.